ACD856 explained

Routes Of Administration:Oral
Class:Tropomyosin receptor kinase TrkA, TrkB, and TrkC positive allosteric modulator
Elimination Half-Life:~19hours
Synonyms:ACD-856

ACD856, or ACD-856, is a tropomyosin receptor kinase TrkA, TrkB, and TrkC positive allosteric modulator which is under development for the treatment of Alzheimer's disease, depressive disorders, sleep disorders, and traumatic brain injuries.[1] [2] [3] [4] [5] [6] It is taken by mouth.

Pharmacology

The drug potentiates the tropomyosin receptor kinases TrkA, TrkB, and TrkC with values of 382nM, 295nM, and ~330nM, respectively. As a positive allosteric modulator of TrkA and TrkB, ACD856 potentiates the effects of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF).[7]

In addition to the tropomyosin receptor kinases, ACD856 is also a similarly potent positive allosteric modulator of certain other receptor tyrosine kinases, including the insulin-like growth factor 1 receptor (IGF1R) and the fibroblast growth factor receptor 1 (FGFR1). However, its efficacies at the IGF1R and FGFR1 were much lower than at the TrkA, TrkB, and TrkC.

In animals, ACD856 has been found to reverse scopolamine- and dizocilpine (MK-801)-induced memory impairment, to improve age-related memory deficits, and to have sustained antidepressant-like activity.[8] It has also been reported to possess neuroprotective properties.

In humans, the drug has been shown to cross the blood–brain barrier and to induce dose-dependent changes in electroencephalogram parameters.[9] No significant tolerability or safety concerns have been identified in preclinical research or phase 1 clinical trials. The drug's clinical pharmacokinetics have been characterized and its elimination half-life is approximately 19hours.[10]

Chemistry

The chemical structure of ACD856 has not yet been disclosed as of 2024, but the structure of its predecessor ponazuril (ACD855) is known and both ponazuril and ACD856 have been described as triazinetriones.

History

It was discovered through the use of high-throughput screening of 25,000compounds. Toltrazuril and ponazuril (ACD855), two veterinary antiparasitic agents, were identified as possessing Trk-potentiating activity with this screen in 2013. ACD856 was derived via structural optimization of these compounds. In the case of ponazuril, this drug was said to have had too long of an elimination half-life to allow for development for use in humans. ACD856 was first described in the scientific literature by 2021.[11]

Clinical trials

As of May 2024, ACD856 is in phase 1 clinical trials for Alzheimer's disease and is in the preclinical stage of development for depressive disorders, sleep disorders, and traumatic brain injuries. Two phase 1 trials have been completed.[12] A phase 2 clinical trial for Alzheimer's disease is being planned as of May 2024. The drug is under development by AlzeCure Pharma AB.

Notes and References

  1. Web site: ACD 856 . AdisInsight . Springer Nature Switzerland AG . 17 May 2024 . 23 October 2024.
  2. Web site: Delving into the Latest Updates on ACD-856 with Synapse . Synapse . 12 October 2024 . 23 October 2024.
  3. Web site: ACD856 . ALZFORUM . 19 December 2023 . 23 October 2024.
  4. Forsell P, Parrado Fernández C, Nilsson B, Sandin J, Nordvall G, Segerdahl M . Positive Allosteric Modulators of Trk Receptors for the Treatment of Alzheimer's Disease . Pharmaceuticals . 17 . 8 . 997 . July 2024 . 39204102 . 11357672 . 10.3390/ph17080997 . free .
  5. Wang D, Lang ZC, Wei SN, Wang W, Zhang H . Targeting brain-derived neurotrophic factor in the treatment of neurodegenerative diseases: A review . Neuroprotection . Wiley . 2 . 2 . 2 May 2024 . 2770-7296 . 10.1002/nep3.43 . free . 67–78 . ACD856 is an innovative allosteric modulator that positively affects all Trk receptors, amplifying their kinase activity. Subsequently, it potentiates the effect of BDNF or nerve growth factor (NGF) on neuronal survival, function, and plasticity of synapses. The finished phase I study showed that ACD856 passed the blood‐brain barrier and induced dose‐dependent treatment‐related alterations in quantitative electroencephalogram parameters with good safety.141,142.
  6. Dahlström M, Madjid N, Nordvall G, Halldin MM, Vazquez-Juarez E, Lindskog M, Sandin J, Winblad B, Eriksdotter M, Forsell P . Identification of Novel Positive Allosteric Modulators of Neurotrophin Receptors for the Treatment of Cognitive Dysfunction . Cells . 10 . 8 . 1871 . July 2021 . 34440640 . 8391421 . 10.3390/cells10081871 . free .
  7. Parrado Fernandez C, Juric S, Backlund M, Dahlström M, Madjid N, Lidell V, Rasti A, Sandin J, Nordvall G, Forsell P . Neuroprotective and Disease-Modifying Effects of the Triazinetrione ACD856, a Positive Allosteric Modulator of Trk-Receptors for the Treatment of Cognitive Dysfunction in Alzheimer's Disease . International Journal of Molecular Sciences . 24 . 13 . 11159 . July 2023 . 37446337 . 10342804 . 10.3390/ijms241311159 . free .
  8. Madjid N, Lidell V, Nordvall G, Lindskog M, Ögren SO, Forsell P, Sandin J . Antidepressant effects of novel positive allosteric modulators of Trk-receptor mediated signaling - a potential therapeutic concept? . Psychopharmacology . 240 . 8 . 1789–1804 . August 2023 . 37394539 . 10349764 . 10.1007/s00213-023-06410-x .
  9. Önnestam K, Nilsson B, Rother M, Rein-Hedin E, Bylund J, Anderer P, Kemethofer M, Halldin MM, Sandin J, Segerdahl M . Safety, Tolerability, Pharmacokinetics and Quantitative Electroencephalography Assessment of ACD856, a Novel Positive Allosteric Modulator of Trk-Receptors Following Multiple Doses in Healthy Subjects . The Journal of Prevention of Alzheimer's Disease . 10 . 4 . 778–789 . 2023 . 37874100 . 10.14283/jpad.2023.89 .
  10. Nilsson B, Bylund J, Halldin MM, Rother M, Rein-Hedin E, Önnestam K, Segerdahl M . ACD856, a novel positive allosteric modulator of Trk receptors, single ascending doses in healthy subjects: Safety and pharmacokinetics . European Journal of Clinical Pharmacology . 80 . 5 . 717–727 . May 2024 . 38353689 . 11001683 . 10.1007/s00228-024-03645-1 .
  11. Nordvall G, Madjid N, Backlund M, Halldin M, Rother M, Nilsson B, Sandin J, Forsell P . ACD856: A novel positive allosteric modulator of Trk-signaling in clinical development for the treatment of Alzheimer's disease . Alzheimer's & Dementia . Wiley . 17 . S9 . 2021 . 1552-5260 . 10.1002/alz.057730 . free . e057730 .
  12. Nordvall G, Forsell P, Sandin J . Neurotrophin-targeted therapeutics: A gateway to cognition and more? . Drug Discovery Today . 27 . 10 . 103318 . October 2022 . 35850433 . 10.1016/j.drudis.2022.07.003 . free .